NO20092226L - Substituerte pyrazol og triazolforbindelser som KSP-inhibitorer - Google Patents

Substituerte pyrazol og triazolforbindelser som KSP-inhibitorer

Info

Publication number
NO20092226L
NO20092226L NO20092226A NO20092226A NO20092226L NO 20092226 L NO20092226 L NO 20092226L NO 20092226 A NO20092226 A NO 20092226A NO 20092226 A NO20092226 A NO 20092226A NO 20092226 L NO20092226 L NO 20092226L
Authority
NO
Norway
Prior art keywords
triazole compounds
substituted pyrazole
ksp inhibitors
pharmaceutically acceptable
ksp
Prior art date
Application number
NO20092226A
Other languages
English (en)
Norwegian (no)
Inventor
Paul A Renhowe
Yi Xia
Kris Mendenhall
Paul A Barsanti
Annette O Walter
David Duhl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20092226L publication Critical patent/NO20092226L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20092226A 2006-11-13 2009-06-09 Substituerte pyrazol og triazolforbindelser som KSP-inhibitorer NO20092226L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85896406P 2006-11-13 2006-11-13
PCT/US2007/084154 WO2008063912A1 (en) 2006-11-13 2007-11-08 Substituted pyrazole and triazole compounds as ksp inhibitors

Publications (1)

Publication Number Publication Date
NO20092226L true NO20092226L (no) 2009-08-12

Family

ID=39144618

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092226A NO20092226L (no) 2006-11-13 2009-06-09 Substituerte pyrazol og triazolforbindelser som KSP-inhibitorer

Country Status (32)

Country Link
US (2) US8129358B2 (pt)
EP (1) EP2091926B1 (pt)
JP (1) JP5264755B2 (pt)
KR (1) KR20090081020A (pt)
CN (1) CN101558049B (pt)
AR (1) AR063805A1 (pt)
AU (1) AU2007323998B2 (pt)
BR (1) BRPI0719002A2 (pt)
CA (1) CA2668661A1 (pt)
CL (1) CL2007003272A1 (pt)
CO (1) CO6382171A2 (pt)
CR (1) CR10787A (pt)
DO (1) DOP2009000106A (pt)
EA (1) EA017748B1 (pt)
EC (1) ECSP099326A (pt)
ES (1) ES2557478T3 (pt)
GE (1) GEP20125389B (pt)
GT (1) GT200900122A (pt)
HN (1) HN2009000968A (pt)
IL (1) IL198471A0 (pt)
MA (1) MA30959B1 (pt)
MX (1) MX2009005071A (pt)
NI (1) NI200900084A (pt)
NO (1) NO20092226L (pt)
NZ (1) NZ576640A (pt)
PE (1) PE20081169A1 (pt)
SM (1) SMP200900045B (pt)
TN (1) TN2009000178A1 (pt)
TW (1) TW200831480A (pt)
UA (1) UA97256C2 (pt)
WO (1) WO2008063912A1 (pt)
ZA (1) ZA200902940B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009005071A (es) * 2006-11-13 2009-05-25 Novartis Ag Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.
CA2674318A1 (en) * 2007-01-05 2008-07-17 Novartis Ag Cyclized derivatives as eg-5 inhibitors
EA201201404A1 (ru) * 2010-04-15 2013-04-30 Новартис Аг Триазолы как ингибиторы кбв (кинезин-белок веретена)
WO2011128388A2 (en) * 2010-04-15 2011-10-20 Novartis Ag Oxazole and thiazole compounds as ksp inhibitors
MX355439B (es) * 2012-12-05 2018-04-18 Merck Sharp & Dohme Proceso para preparar inhibidores de la transcriptasa inversa.
EP2968591A1 (en) * 2013-03-15 2016-01-20 Novartis AG Cell proliferation inhibitors and conjugates thereof
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
CA2930585A1 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
US20190161499A1 (en) * 2015-12-11 2019-05-30 Syngenta Participations Ag Pesticidally active 1,2,4-triazole derivatives
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5185450A (en) * 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
AUPP042397A0 (en) * 1997-11-18 1997-12-11 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds
EP1165519A1 (en) 1999-04-02 2002-01-02 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
BR0015110A (pt) 1999-10-27 2002-07-02 Cytokinetics Inc Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos
MXPA03003039A (es) 2000-10-06 2003-10-15 Neurogen Corp Derivados de indola y bencimidazola como moduladores del receptor crf.
US20040132830A1 (en) 2001-01-19 2004-07-08 Finer Jeffrey T Triphenylmethane kinesin inhibitors
WO2002057244A1 (en) 2001-01-19 2002-07-25 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
EP1444209A4 (en) 2001-11-07 2005-02-16 Merck & Co Inc INHIBITORS OF MITOTIC KINESINS
EP1450816A4 (en) 2001-11-08 2008-02-13 Univ Chicago METHOD OF TREATING DISORDERS RELATED TO HIGH CHOLESTEROL RATE
US6753428B2 (en) 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
ATE372341T1 (de) 2001-12-06 2007-09-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
JP4391825B2 (ja) 2001-12-06 2009-12-24 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
WO2003049527A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2005515208A (ja) 2001-12-06 2005-05-26 メルク エンド カムパニー インコーポレーテッド 有糸分裂性キネシン阻害剤
JP4467979B2 (ja) 2001-12-06 2010-05-26 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
AU2002357114B2 (en) * 2001-12-07 2008-07-24 Virginia Commonwealth University Treatment of neoplasia
WO2003059289A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
WO2003070701A2 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Syntheses of quinazolinones
WO2003079973A2 (en) 2002-03-08 2003-10-02 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
WO2003094839A2 (en) 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
WO2004026226A2 (en) 2002-05-10 2004-04-01 Cytokinetics, Inc. Compounds, compositions and methods
JP2005536475A (ja) 2002-05-23 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
US20050234080A1 (en) 2002-05-23 2005-10-20 Coleman Paul J Mitotic kinesin inhibitors
KR20050010515A (ko) 2002-06-14 2005-01-27 머크 앤드 캄파니 인코포레이티드 유사분열 키네신 억제제
US7301028B2 (en) 2002-06-14 2007-11-27 Merck & Co., Inc. Mitotic kinesin inhibitors
GB0214139D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
WO2004004652A2 (en) 2002-07-08 2004-01-15 Merck & Co., Inc. Mitotic kinesin binding site
WO2004006865A2 (en) 2002-07-17 2004-01-22 Cytokinetics, Inc. Compounds, compositions, and methods
EP1537089A4 (en) 2002-07-23 2008-04-16 Cytokinetics Inc CONNECTIONS, COMPOSITIONS AND PROCEDURES
AU2003262747A1 (en) 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005539062A (ja) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
US20080021079A1 (en) 2003-05-07 2008-01-24 Han-Jie Zhou Compounds, Compositions, and Methods
JP2007500746A (ja) 2003-05-15 2007-01-18 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
PT1732926E (pt) * 2004-04-06 2009-04-03 Novartis Vaccines & Diagnostic Inibidores de cinesinas mitóticas
CA2564215A1 (en) 2004-05-21 2005-12-01 Chiron Corporation Substituted quinoline derivatives as mitotic kinesin inhibitors
JP4836280B2 (ja) * 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド 癌を治療するためのキネシンスピンドルタンパク質(ksp)阻害剤としてのn−(1−(1−ベンジル−4−フェニル−1h−イミダゾール−2−イル)−2,2−ジメチルプロピル)ベンズアミド誘導体および関連化合物
KR20070072598A (ko) * 2004-10-19 2007-07-04 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 인돌 및 벤지미다졸 유도체
US7829589B2 (en) * 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
TW200800951A (en) * 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
MX2009005071A (es) * 2006-11-13 2009-05-25 Novartis Ag Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.

Also Published As

Publication number Publication date
CA2668661A1 (en) 2008-05-29
JP5264755B2 (ja) 2013-08-14
AR063805A1 (es) 2009-02-18
SMP200900045B (it) 2010-03-01
EA017748B1 (ru) 2013-02-28
KR20090081020A (ko) 2009-07-27
EP2091926B1 (en) 2015-10-21
HN2009000968A (es) 2011-10-25
EP2091926A1 (en) 2009-08-26
ZA200902940B (en) 2010-05-26
TN2009000178A1 (en) 2010-10-18
US8129358B2 (en) 2012-03-06
US20080200462A1 (en) 2008-08-21
JP2010509365A (ja) 2010-03-25
TW200831480A (en) 2008-08-01
CN101558049B (zh) 2012-08-15
BRPI0719002A2 (pt) 2013-12-17
US20100034813A1 (en) 2010-02-11
CL2007003272A1 (es) 2008-03-24
GT200900122A (es) 2011-09-14
AU2007323998B2 (en) 2011-09-22
ECSP099326A (es) 2009-06-30
CR10787A (es) 2009-07-02
DOP2009000106A (es) 2009-05-31
MA30959B1 (fr) 2009-12-01
WO2008063912A1 (en) 2008-05-29
NI200900084A (es) 2010-01-29
MX2009005071A (es) 2009-05-25
PE20081169A1 (es) 2008-09-24
SMAP200900045A (it) 2009-07-14
CO6382171A2 (es) 2012-02-15
UA97256C2 (ru) 2012-01-25
ES2557478T3 (es) 2016-01-26
NZ576640A (en) 2011-10-28
AU2007323998A1 (en) 2008-05-29
IL198471A0 (en) 2010-02-17
GEP20125389B (en) 2012-01-25
US7902240B2 (en) 2011-03-08
CN101558049A (zh) 2009-10-14
EA200900631A1 (ru) 2009-12-30

Similar Documents

Publication Publication Date Title
NO20092226L (no) Substituerte pyrazol og triazolforbindelser som KSP-inhibitorer
UA97821C2 (en) Cyclized derivatives as eg-5 inhibitors
MX2011013771A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17.
NO20083669L (no) 4-aryl-2amino-pyrimidiner eller 4-aryl-2-aminoalkylpyrimidiner som jak-2-modulatorer og fremgangsmater for anvendelse derav
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
MX2007004699A (es) Derivados de indol y bencimidazol.
MX2009008506A (es) Derivados del pirazol como inhibidores de 11-b-hsd1.
NO20083717L (no) Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorer
TW200612958A (en) Substituted imidazole derivatives
ECSP10010447A (es) Inhibidores de cinasa pim y métodos para su uso
WO2008075172A3 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
MX2012004089A (es) Inhibidores de hsp90.
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
WO2007117465A3 (en) Indazole compounds
NO20083726L (no) Spiroindolinon derivater
TW200833324A (en) Sulfonamide derivatives
MX2012003982A (es) Pirrolidinas n-substituidas.
PH12012502216A1 (en) Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienyl-methylbenzene derivatives as inhibitors of sglt
MX2009010302A (es) Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion.
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
NO20084543L (no) Benzimidazolderivater
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
MX2009013003A (es) Derivados de piperidina-amida.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application